Grifols, a CataloniaBio & HealthTech member, welcomes the promising post-hoc analysis recently published by Biotest AG on the efficacy of trimodulin1 (IgM concentrate) in a relevant subgroup of severely ill COVID-19 patients.
In September, Grifols announced it entered into an agreement to acquire Tiancheng (Germany) Pharmaceutical Holdings for EUR 1,100 million, the largest owner of Biotest AG. An alliance that will boost the availability of plasma-derived medicines and increase access for patients.
Less than one month after announcing the investment, Grifols welcomes Biotest’s recent and promising results: the analysis of the complete data set of ESsCOVID (Escape from severe COVID-19). The detailed post-hoc analyses revealed a notable benefit in a relevant subgroup of hospitalized patients with early systemic inflammation. In this subgroup of 96 COVID-19 patients, trimodulin markedly reduced the progression and mortality of patients compared to the placebo group.
In recent quarters, Grifols has expanded and diversified its access to plasma, as well as reinforced its plasma-centre leadership, with 350 plasma donation centres across the United States and Europe.
Photo: Raimon Grífols and Víctor Grífols Deu, CEOs of Grifols
Comments